Keywords
osteosarcoma
acute toxicity
laboratory mice
miR162a
lipofectamine
Abstract
MicroRNAs are inhibitors that suppress the expression of specific genes. mTOR is a mammalian target of rapamycin, which is a key regulator of molecular mechanisms related to cell growth, proliferation and survival during oncogenesis. The microRNA miR162a is involved in the control of mTOR gene expression by affecting activity. There is evidence that miR162a has therapeutic potential as a tool for pathogenetic therapy of tumor diseases.
The aim of work was to investigate the acute toxicity of the pharmacological formulation, based on microRNA miR162a in vivo in a laboratory mouse model.
Materials and methods. A pharmacological formulation was developed. Thirty male ICR outbred mice divided into two experimental groups (I and II) and a control group were used for the study. The solution was administered to the mice intraperitoneally in therapeutic and supratherapeutic doses to group I and II, respectively. In 14 days after the drug administration, the following organs were harvested from all mice in each group: liver, kidneys, heart, lungs, testes. Histological examination of the obtained organs was performed, morphometric study was carried out in kidneys and testes. Statistical processing of data was performed using R-4.4.1.
Results. In terms of overall survival: LD50 was not reached. No significant structural changes were found in the experimental groups by histological examination. The morphometry results also confirm that no statistically significant differences were found between the experimental groups and the control group.
Conclusion. The miR162a-based pharmacological formulation had no acute toxic effects on liver, kidney, lung, myocardium and testes.
For citation
Kornilov DO, Petrov VM, Simarzina VM, Tryapitsyn MA, Zornikov DL, Gordienko II, et al. In vivo acute toxicity study of miR162a-based pharmacological formulation in a laboratory mouse model. USMU Medical Bulletin. 2024;(3):25–36. (In Russ.). EDN: https://elibrary.ru/NVSXGK.
References
miRNAs as Biomarkers of Myocardial Infarction: Meta-Analysis / C. Cheng, Q. Wang, W. You [et al.] // PLoS One. 2014. Vol. 9, Iss. 2, Art. No. e88566. DOI: https://doi.org/10.1371/journal.pone.0088566.
Plant microRNAs in Larval Food Regulate Honey Bee Caste Development / K. Zhu, M. Liu, Z. Fu [et al.] // PLoS Genetics. 2017. Vol. 13, Iss. 8, Art. No. e1006946. DOI: https://doi.org/10.1371/journal.pgen.1006946.
Saxton R. A., Sabatini D. M. mTOR Signaling in Growth, Metabolism, and Disease // Cell. 2017. Vol. 168, Iss. 6. P. 960–976. DOI: https://doi.org/10.1016/j.cell.2017.02.004.
Weichhart T. mTOR as Regulator of Lifespan, Aging, and Cellular Senescence: A Mini-Review // Gerontology. 2017. Vol. 84, Iss. 2. P. 127–134. DOI: https://doi.org/10.1159/000484629.
Schreiber K. H., Kennedy B. K. When Lamins Go Bad: Nuclear Structure and Disease // Cell. 2013. Vol. 152. P. 1365–1375. DOI: https://doi.org/10.1016/j.cell.2013.02.015.
Ингибирование опухолевого роста в клеточной культуре остеосаркомы с помощью микроРНК miR162a / Д. Ю. Гребнев, И. Ю. Маклакова, Д. О. Корнилов [и др.] // Патологическая физиология и экспериментальная терапия. 2023. Т. 67, № 1. С. 48–55. DOI: https://doi.org/10.25557/0031-2991.2023.01.48-55.
Advanced Transfection with Lipofectamine 2000 Reagent: Primary Neurons, siRNA, and High-Throughput Applications / B. Dalby, S. Cates, Adam Harris [et al.] // Methods. 2004. Vol. 33, Iss. 2. P. 95–103. DOI: https://doi.org/10.1016/j.ymeth.2003.11.023.
Invivofectamine™ 3.0 Reagent / Invitrogen. URL: https://clck.ru/3DmJXM (date of access: 12.03.2023).
Liver Bid Suppression for Treatment of Fibrosis Associated with Non-alcoholic Steatohepatitis / A. Eguchi, X. De Mollerat Du Jeu, C. D. Johnson [et al.] // Journal of Hepatology. 2016. Vol. 64, Iss. 3. P. 699–707. DOI: https://doi.org/10.1016/j.jhep.2015.11.002.
Богданов Л. А., Шишкова Д. К., Кутихин А. Г. Сравнение различных видов прогрессивных гематоксилинов при окрашивании элементов системы кровообращения и гепатолиенальной системы // Сибирский научный медицинский журнал. 2019. Т. 39, № 6. С. 46–54. DOI: https://doi.org/10.15372/SSMJ20190606.
The Synthesis and Application of Nano Doxorubicin-Indocyanine Green Matrix Metalloproteinase-Responsive Hydrogel in Chemophototherapy for Head and Neck Squamous Cell Carcinoma / H.-H. Wang, Z.-G. Fu, W. Li [et al.] // International Journal of Nanomedicine. 2019. Vol. 14. P. 623–638. DOI: https://doi.org/10.2147/IJN.S191069.
TRAIL and Curcumin Codelivery Nanoparticles Enhance TRAIL-Induced Apoptosis Through Upregulation of Death Receptors / X. Yang, Z. Li, Q. Wu [et al.] // Drug Delivery. 2017. Vol. 24, Iss. 1. P. 1526–1536. DOI: https://doi.org/10.1080/10717544.2017.1384863.
A Chrysin Derivative Suppresses Skin Cancer Growth by Inhibiting Cyclin-Dependent Kinases / H. Liu, K. Liu, Z. Huang [et al.] // Journal of Biological Chemistry. 2013. Vol. 288, Iss. 36. P. 25924–25937. DOI: https://doi.org/10.1074/jbc.m113.464669.
Abstract B50: Per Oral Nanogel Conjugates of Activated Nucleoside Analogs are Effective in the Treatment of Drug-Resistant Tumors / T. H. Senanayake, G. Warren, S. K. Batra [et al.] // Clinical Cancer Research. 2012. Vol. 18, Iss. 10, Suppl., Art. No. B50. DOI: https://doi.org/10.1158/1078-0432.MECHRES-B50.
TRIM44, a Crucial Target of miR-410, Functions as a Potential Oncogene in Osteosarcoma / H. Wang, Z. L. Fang, G.-H. Zhang, X. Ma // OncoTargets and Therapy. 2018. Vol. 11. P. 3637–3647. DOI: https://doi.org/10.2147/OTT.S163163.
The Proliferation and Invasion of Osteosarcoma are Inhibited by miR-101 via Targeting ZEB2 / H. Lin, X. Zheng, T. Lu [et al.] // Bioscience Reports. 2019. Vol. 39, Iss. 2, Art. No. BSR20181283. DOI: https://doi.org/10.1042/BSR20181283.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
Copyright © 2024 Kornilov D. O., Petrov V. M., Simarzina V. M., Tryapitsyn M. A., Zornikov D. L., Gordienko I. I., Koznova A. E., Valamina I. E.